Key result
Dexmedetomidine infusion at 0.5 µg/kg/h significantly reduced mean arterial pressure and heart rate during and up to 4 hours after coronary artery bypass grafting surgery compared to saline.
Why the study?
To determine the effect of dexmedetomidine on left ventricular function and its ability to attenuate hemodynamic responses to surgical stress during and after CABG surgery.
Does a continuous infusion of dexmedetomidine improve hemodynamic stability and left ventricular function in patients undergoing elective CABG surgery?
RCT (n=64)
Single-blind
Computer-generated program
No
Does a continuous infusion of dexmedetomidine improve hemodynamic stability and left ventricular function in patients undergoing elective CABG surgery?
p-value: p=<0.05
Pretreatment with a 0.5 µg/kg/h dexmedetomidine infusion in elective CABG surgery safely attenuates stress-induced hemodynamic reactions and reduces postoperative atrial fibrillation, though it increases the requirement for inotropic support.
No takes yet. Share an insight, caveat, or question.
Dexmedetomidine attenuates hemodynamic surges during CABG without altering ejection fraction; extends hemodynamic evidence while leaving LV function effects open.
Hussien et al. (2025) conducted an RCT in Coronary Artery Bypass Grafting (CABG) surgery (n=64). Dexmedetomidine vs. 0.9% saline was evaluated on Mean arterial pressure (MAP) changes during the study period (p=<0.05). Dexmedetomidine infusion at 0.5 µg/kg/h significantly reduced mean arterial pressure and heart rate during and up to 4 hours after coronary artery bypass grafting surgery compared to saline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: